BASEL (Reuters) – Swiss drugmaker Novartis on Wednesday predicted that core operating income would grow in a “mid single digit” percentage range in 2023, following stagnation last year.
Full-year core operating income was broadly flat at $16.7 billion, it said in a statement.
(Reporting by Ludwig Burger; Editing by Paul Carrel)
